|
Tuesday 4th October 2022 |
Text too small? |
Cannasouth Limited (NZX: CBD ) is pleased to announce that it has received its first shipment of verified cannabis medicines.
Cannasouth CEO Mark Lucas says, “This accomplishment marks the end of a near two-year process since submitting product assessments with the Medicinal Cannabis Agency.
"The differentiated formulations of our products will provide New Zealand patients and prescribers with new treatment options compared to existing products on the New Zealand market. We are confident these products offer patients and prescribers a point of difference to meet the treatment needs of a wider range of conditions.”
Navigating and establishing the supply chain for its first medicines means Cannasouth is now generating revenue from the sale of medicines in New Zealand.
A list of all medicinal cannabis products that meet the New Zealand minimum quality standard can be found here: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis-agency-information-health-professionals/medicinal-cannabis-products-meet-minimum-quality-standard
-ENDS-
NXZ MAP_First Verified Cannabis Medicines Received
No comments yet
TEM - Transaction in Own Shares
October 9th Morning Report
VGL - NZX Tech Investor Day Presentation
October 8th Morning Report
IFT - CDC Independent Valuation
TEM - Transaction in Own Shares
October 7th Morning Report
Devon Funds Morning Note - 06 October 2026
AFT reports double digit revenue growth in 1H FY27
TEM - Transaction in Own Shares